Latest News

2019

• Press Release: Paras Biopharmaceuticals Finland Oy Announces Successful Development of Biologically Active Romiplostim (N-Plate® Biosimilar) Production Technology
• Paras Biopharmaceuticals confirms its attendance at:
  • BIO Europe Spring in Vienna
  • BIO Korea in Seoul
  • BIO International Convention in Philadelphia
  • Nordic Life Science Days in Stockholm
  • Festival of Biologics in Basel

News Archive

2017 - 2018

• Press Release: Affordable Healthcare in Oulu Closer than Ever: Paras Biopharmaceuticals Finland Oy Significantly Invests in Oulu Biologics Production Site
• Paras Biopharmaceuticals acquires new Agilent Q-TOF to expand analytical capabilities
• Paras Biopharmaceuticals receives Quality Choice award from European Society for Quality Research, Switzerland
• Biochemistry Students participate in fact-finding tour of GMP facility
• New team members join Paras Biopharmaceuticals.
• Paras Biopharmaceuticals upgrades its purification suite to expand existing capabilities.
• Paras Biopharmaceuticals expands its purification suite with the addition of low-pressure AxiChrom columns from GE Healthcare Life Sciences.
• Oulu-based Paras Biopharmaceuticals develops technology for Osteoporosis biosimilar drug & brings international investments. Expansion scheduled in Oulu.

2015 - 2016

• Paras Biopharmaceuticals Finland Oy Selected as First Finnish Company to Present at Cavendish Global Health Impact Forum.
• Paras Biopharmaceuticals wins the 2014 European Biopharmaceuticals Technology Innovation Leadership Award by Frost & Sullivan.
• Paras achieves quality, bio efficacy and potency in its Forteo Biosimilar product. Clinical studies to begin.
• Dr Hans Söderlund, Director of Global Strategic Alliance will be the Key-note speaker at "Reshaping Human Life Through Biotechnology" conference organised by the Gujarat State Biotechnology Mission (GSBTM), Mahatma Mandir, Gandhinagar.
• Paras Biopharmaceuticals facilities in Finland upgraded with additional equipment.
• New team members join Paras Biopharmaceuticals in its efforts to double-up and deliver quality biotherapeutics.
• Paras’ labs achieve high titers and production expression levels for anti-diabetic and osteoporosis recombinant therapeutic proteins.
• Paras Biopharmaceuticals expands its core- team of management professionals. Looking for strategic tie ups on technology licensing.
• Paras Biopharmaceuticals representative participates in “Business Innovations in Global Healthcare Program” in Harvard Business School (HBS), Boston, M.A, USA.

2014

• Paras Biopharmaceuticals Finland Oy successfully develops long acting analog insulin – Biosimilar with very high yield and process which gives way for its economical production at industrial scale.
• Clones developed by Paras Biopharmaceuticals Finland Oy stored in additional location in Germany.
• Paras Biopharmaceuticals Finland Oy completes Diabrid Expressions, visualization of Diabrid in E. Coli.

2012 - 2013

• The company achieves New Diabrid expressions and purification for therapeutic peptides/biologics of high value.
• Company filing PCT patents on Diabrid technology.
• Company invited to participate in Jefferies Global Healthcare Investment meets in New York (June 3-6, 2013).
• Technology development team of Paras achieves robust Crystals for Rheumatoid Arthritis product.
• Company team makes a successful trip to India to shortlist Joint Venture partner.
• Company in advanced discussion with technology licensing.

Past

• A new & innovative approach incorporated into Diabrid expressions.
• Paras Biopharmaceuticals Finland Oy initiates discussions for possible patents / propriety use for expression of biopharmaceuticals.
• Gene code optimization achieved for Diabrid expressions.
• Paras Biopharmaceuticals Finland Oy collaborates with an expert lab group in the USA.
• Conceptual work on Diabrid Technology initiated.